Business Information
The group's principal activities are to develop, manufacture and market generic and proprietary pharmaceutical products. The group manufactures and markets more than 57 pharmaceutical products, representing various dosage strengths and product forms of approximately 54 chemical entities. The product line is focused on proprietary products in oncology, female healthcare, cardiovascular, anti-infectives and psychotherapeutics. The group's major brands include desogen (R), ortho-cept (R), alesse (R), danocrine (R), adderall (R), dexedrine (R), spansule (R), persantine (R), prozac (R), mircette (R), levlite (R), provera (R), rheumatrex (R), aygestin(R) and coumadin (r). The group operates throughout the United States, Puerto Rico and Canada. On 26-Feb-2004, the group acquired women's capital corporation.
|
|
Name |
Title
|
Email
|
| Bruce Downey | Chmn., CEO | N/A | | Frederick Wilkinson | Pres., COO - Duramed Pharmaceuticals, Inc | N/A | | Marc Kustoff | CIO, Sr. VP | N/A | | Amy Niemann | Sr. VP - Proprietary Marketing | N/A | | Carol Cox | Sr. VP - Global Investor Relations, Corporate Communications | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 1,314,465 | 336,477 | | 2005 | 1,047,399 | 214,988 | | 2006 | 916,403 | (338,155)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
